KR20200023576A - Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component - Google Patents
Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component Download PDFInfo
- Publication number
- KR20200023576A KR20200023576A KR1020180098974A KR20180098974A KR20200023576A KR 20200023576 A KR20200023576 A KR 20200023576A KR 1020180098974 A KR1020180098974 A KR 1020180098974A KR 20180098974 A KR20180098974 A KR 20180098974A KR 20200023576 A KR20200023576 A KR 20200023576A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- fermented
- composition
- white spotted
- liver function
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000003908 liver function Effects 0.000 title claims abstract description 20
- 241000767510 Protaetia brevitarsis Species 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 14
- 230000007882 cirrhosis Effects 0.000 claims abstract description 7
- 241000220259 Raphanus Species 0.000 claims description 30
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 29
- 238000000855 fermentation Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 241000111850 Protaetia brevitarsis seulensis Species 0.000 abstract 4
- 229940124316 agent for liver cirrhosis Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 16
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 241000237858 Gastropoda Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000007602 hot air drying Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000254068 Cetoniinae Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000254062 Scarabaeidae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- -1 pH regulators Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving liver function containing fermented white spotted radish larvae extract as an active ingredient.
현대인의 간 손상 원인은 다양하며, 알코올, 흡연 외에도 바이러스에 의한 감염, 독물 또는 약제에 의한 중독, 영양장애 및 순환장애, 스트레스 같은 신변의 원인 등이 있다. 특히 바이러스나 음주에 의해서 가장 많이 발생하는 간염이나, 간암은 확실한 치료약이 없기 때문에 치유보다는 더이상 질병이 진행되지 않도록 하는 소극적 치료 조절에 의존하고 있는 것이 대부분의 실정이다. 또한, 한국인의 간암에 의한 사망률은 10만 명당 23.4명으로 세계 1위이고, 만성 간질환의 경우도 28.8명으로 3위로 조사되었으며, 최근 통계청에서 우리나라 40대의 경우 인구 10만 명당 56.1명이 간질환을 앓고 있다고 발표하였다. There are various causes of liver damage in modern people, and in addition to alcohol and smoking, there are viral infections, poisoning with poisons or drugs, nutritional disorders, circulatory disorders, and other causes of stress such as stress. In particular, hepatitis and liver cancer, which are most frequently caused by viruses or alcohol, have no cure, and most of them rely on passive treatment control to prevent the disease from progressing. In addition, the mortality rate of liver cancer among Koreans was 23.4 per 100,000, ranking first in the world, and chronic liver disease was ranked 3rd with 28.8. Recently, the National Statistical Office reported that 56.1 people per 100,000 population in Korea in their 40s. Announced that he was sick.
이러한 간 관련 질병에 의한 폐해가 커짐에 따라서 간 관련 치료제 시장뿐만 아니라 건강기능성 식품시장에도 간 기능성 개선 제품에 대한 관심과 소비자의 요구도가 높아지고 있는 실정이다. 따라서 간을 보호하고 치유하는 효과가 있는 약물이나 기능성 식품을 개발하는 것은 대단히 중요하며, 간 질환의 치료를 위한 합성 의약품에 관한 보고가 있으나 합성 의약품은 부작용과 독성을 간과할 수 없기 때문에, 천연물로부터 부작용 없는 간 기능 개선제와 이를 위한 자연식품의 개발이 절실한 실정이다.As the damage caused by liver-related diseases increases, the interest and demand of consumers for liver functional improvement products are increasing not only in the liver-related therapeutic market but also in the health functional food market. Therefore, it is very important to develop drugs or functional foods that have the effect of protecting and healing the liver, and there are reports of synthetic medicines for the treatment of liver disease, but synthetic medicines cannot be overlooked from side effects and toxicity. There is an urgent need to develop liver function improving agents without side effects and natural foods for them.
한편, 흰점박이꽃무지는 민간 및 동의보감(東醫寶鑑) 등의 전통 한방의서에서 '제조' 또는 '굼벵이'라는 속명으로 불리고 있는 딱정벌레목(Coleoptera), 풍뎅이과(Scarabaeidae), 꽃무지아과(Cetoniinae)에 속하는 크기 17~24㎝의 식식성(phytophagous) 곤충으로, 우리나라를 비롯하여 중국, 일본 및 시베리아 동부 지역에 서식하는 것으로 알려져 있다. On the other hand, the white spotted radish has the name Coleoptera, Scarabaeidae, and the flower radiologist, which are called 'manufacturing' or 'slugs' in traditional Chinese medicine such as folk medicine and Dongbobogam (東 醫 寶 鑑). Cetoniinae) is a phytophagous insect of 17-24 cm in size and is known to live in China, Japan, and Siberia.
흰점박이꽃무지는 3령의 성숙유충 상태로 월동하며, 성충은 주간에 활동하고 복숭아, 배 등의 성숙한 과일이나 옥수수, 상수리 나무 등의 즙액을 먹이로 하며, 항상 군집성이다. 또한, 이들의 유충은 퇴비나 건초더미 등의 유기물이 풍부한 부식성 토양 속에서 서식한다.White spotted radish overwinters as a three-year-old mature larvae. Adults are active during the day and feed on mature fruits such as peaches and pears, or juices such as corn and oak, and are always clustered. Their larvae also live in corrosive soils rich in organic matter such as compost and haystacks.
한편, 흰점박이꽃무지의 기능에 대한 연구는 많이 진행되어 있지만, 미생물을 이용하여 발효를 진행한 연구는 여전히 부족한 실정이다. 여기서 발효란, 미생물이 자신이 가지고 있는 효소를 이용하여 유기물을 분해, 합성 등 다양한 과정을 통해 산화 및 환원시키는 것을 말한다. 이를 통해 유기물의 소화 및 흡수를 용이하게 하고, 새로운 약성이나 약효를 띄게 할 수 있다는 사실이 지속적으로 보고되고 있다. 따라서 흰점박이꽃무지 유충을 균주로 발효시켰을 경우 상당한 시너지 효과가 있을 것으로 기대된다.On the other hand, many studies on the function of the white spotted flower ignorance, but the progress of fermentation using microorganisms is still insufficient. Here, fermentation means that the microorganism is oxidized and reduced through various processes such as decomposition, synthesis, and the like by using an enzyme possessed by the microorganism. It is reported that this can facilitate the digestion and absorption of organic matter, and can bring about new weaknesses or effects. Therefore, it is expected that the synergistic effect of white spotted larva fermented into strains.
한편, 한국등록특허 제1539057호에 산겨릅나무 추출물을 함유하는 간 기능 개선용 음료 조성물이 개시되어 있고, 한국등록특허 제1758718호에는 흰점박이꽃무지 유충으로부터 분리된 화합물을 함유하는 항혈전용 조성물이 개시되어 있지만, 본 발명의 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 조성물에 관해 개시된 바 없다.On the other hand, Korean Patent No. 1539057 discloses a beverage composition for improving liver function containing an extract of mountain bran, and Korean Patent No. 1,175,871 includes an anti-blood composition containing a compound isolated from white spotted larvae Although disclosed, the composition for improving liver function containing fermented white spotted radish larvae extract of the present invention as an active ingredient is not disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 조성물을 제공하고, 상기 발효 흰점박이꽃무지 유충 추출물의 항산화 효과, COLⅠA1의 감소효과, AST 및 ALT의 감소효과를 확인함으로써, 본 발명을 완성하였다.The present invention has been derived by the above requirements, provides a composition for improving liver function containing fermented white spotted radish larvae extract as an active ingredient, the antioxidant effect of the fermented white spotted radish larvae extract, reduction of COL IA1 By confirming the effect, the reduction effect of AST and ALT, the present invention was completed.
상기 과제를 해결하기 위하여, 본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 건강기능식품 조성물을 제공한다. In order to solve the above problems, the present invention provides a health functional food composition for improving liver function containing fermented white spotted radish larvae extract as an active ingredient.
또한, 본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 섬유화 및 간경변의 예방 또는 치료용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention or treatment of liver fibrosis and cirrhosis of the fermented white spotted radish larvae extract as an active ingredient.
본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 조성물에 관한 것으로, 발효 흰점박이꽃무지 유충의 열수 추출물이 세포독성은 없으면서, 항산화 효과, COLⅠA1의 감소효과, AST 및 ALT의 감소효과가 비발효 흰점박이꽃무지 유충의 열수 추출물에 비해 현저하므로, 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 본 발명의 조성물은 간 기능 개선용 건강기능식품 조성물 또는 간 섬유화 및 간경변의 예방 또는 치료용 약학 조성물의 소재로 사용할 수 있다.The present invention relates to a composition for improving liver function comprising fermented white spotted radish larvae extract as an active ingredient, wherein the hydrothermal extract of fermented white spotted radish larvae does not have cytotoxicity, and has an antioxidant effect, a reduction effect of COLIA1, AST and Since the effect of reducing ALT is remarkable compared to the hydrothermal extract of the non-fermented white spotted radish larvae, the composition of the present invention containing fermented white spotted radish larvae extract as an active ingredient is a health functional food composition or liver fibrosis for improving liver function and It can be used as a material of the pharmaceutical composition for the prevention or treatment of cirrhosis.
도 1은 흰점박이꽃무지 유충 추출물의 세포독성을 확인한 결과이다. Control은 아무것도 처리하지 않은 음성대조군이고, F-Pbl-0d는 비발효 흰점박이꽃무지 유충 추출물 처리군이고, F-Pbl-3d는 발효 흰점박이꽃무지 유충 추출물 처리군이다.
도 2는 흰점박이꽃무지 유충 추출물 처리에 의한 인간 간 성상세포(LX-2)의 증식 억제효과를 확인한 결과이다. TGF-β1을 처리하여 세포 증식을 유도하였다. Control은 아무것도 처리하지 않은 음성대조군이고, DPI(diphosphoinositide)는 양성대조군이다. F-Pbl-0d는 500㎍/㎖의 비발효 흰점박이꽃무지 유충 추출물 처리군이고, F-Pbl-3d는 농도별 발효 흰점박이꽃무지 유충 추출물 처리군이다. **은 음성대조군에 비해 TGF-β1 처리시 세포 증식이 유의미하게 증가하였음을 의미하며, p<0.01이다. ##은 TGF-β1 단독 처리군에 비해 F-Pbl-0d 병행 처리군의 세포 증식이 유의미하게 감소하였음을 의미하며, p<0.01이다. @@는 TGF-β1 및 F-Pbl-3d 50㎍/㎖ 처리군에 비해 TGF-β1 및 F-Pbl-3d 250㎍/㎖ 처리군의 세포 증식이 유의미하게 감소하였음을 의미하며, p<0.01이다.
도 3은 흰점박이꽃무지 유충 추출물 처리에 의한 COLⅠA1의 발현 감소효과를 확인한 결과이다. TGF-β1을 처리하여 COLⅠA1의 발현을 유도하였다. Control은 아무것도 처리하지 않은 음성대조군이고, DPI(diphosphoinositide)는 양성대조군이다. F-Pbl-0d는 500㎍/㎖의 비발효 흰점박이꽃무지 유충 추출물 처리군이고, F-Pbl-3d는 농도별 발효 흰점박이꽃무지 유충 추출물 처리군이다. **은 음성대조군에 비해 TGF-β1 처리시 COLⅠA1의 발현이 유의미하게 증가하였음을 의미하며, p<0.01이다. #은 TGF-β1 단독 처리군에 비해 F-Pbl-0d 병행 처리군의 COLⅠA1의 발현이 유의미하게 감소하였음을 의미하며, p<0.05이다. @@는 TGF-β1 및 F-Pbl-0d 처리군에 비해 TGF-β1 및 F-Pbl-3d 50㎍/㎖ 처리군의 COLⅠA1의 발현이 유의미하게 감소하였음을 의미하며, p<0.01이다.
도 4는 흰점박이꽃무지 유충 추출물 처리에 의한 항산화효과를 확인한 결과이다. H2O2를 처리하여 산화를 유도하였다. Control은 아무것도 처리하지 않은 음성대조군이고, F-Pbl-0d는 500㎍/㎖의 비발효 흰점박이꽃무지 유충 추출물 처리군이고, F-Pbl-3d는 농도별 발효 흰점박이꽃무지 유충 추출물 처리군이다. **은 음성대조군에 비해 H2O2 처리시 DCF(dichlorofluorescein)의 강도가 유의미하게 증가하였음을 의미하며, p<0.01이다. ##은 H2O2 단독 처리군에 비해 F-Pbl-0d 병행 처리군의 DCF의 강도가 유의미하게 감소하였음을 의미하며, p<0.01이다. @@는 H2O2 및 F-Pbl-0d 처리군에 비해 H2O2 및 F-Pbl-3d 50㎍/㎖ 처리군의 DCF의 강도가 유의미하게 감소하였음을 의미하며, p<0.01이다.
도 5는 흰점박이꽃무지 유충 추출물 처리에 의한 AST(A) 및 ALT(B)의 활성을 확인한 결과이다. H2O2를 처리하여 효소의 활성을 유도하였다. Control은 아무것도 처리하지 않은 음성대조군이고, DPI(diphosphoinositide)는 양성대조군이다. F-F-Pbl-0d는 500㎍/㎖의 비발효 흰점박이꽃무지 유충 추출물 처리군이고, F-Pbl-3d는 농도별 발효 흰점박이꽃무지 유충 추출물 처리군이다.1 is a result confirming the cytotoxicity of the white spotted radish larvae extract. Control is a negative control group without any treatment, F- Pbl -0d is a non-fermented white spotted flower larvae extract treatment group, F- Pbl -3d is a fermented white spotted flower larvae extract treatment group.
Figure 2 is a result confirming the proliferation inhibitory effect of human liver astrocytic cells (LX-2) by white spotted flower larva extract treatment. TGF-β1 was treated to induce cell proliferation. Control is a negative control without any processing, and diphosphoinositide (DPI) is a positive control. F- Pbl- 0d is a non-fermented white spotted radish larvae extract treatment group of 500 µg / ml, and F- Pbl -3d is a fermented white spotted radish larvae extract treatment group by concentration. ** indicates a significant increase in cell proliferation when treated with TGF-β1 compared to the negative control group, p <0.01. ## means that the cell proliferation of the F- Pbl- 0d parallel treatment group was significantly reduced compared to the TGF-β1 treatment group, and p <0.01. @@ means that the TGF-β1 and F- Pbl -3d 250μg / ml treated groups significantly decreased cell proliferation compared to the TGF-β1 and F- Pbl -3d 50μg / ml treated groups, and p <0.01 to be.
Figure 3 is a result confirming the effect of reducing the expression of COL IA1 by white spotted radish larvae extract treatment. TGF-β1 was treated to induce the expression of COLIA1. Control is a negative control without any processing, and diphosphoinositide (DPI) is a positive control. F- Pbl- 0d is a non-fermented white spotted radish larvae extract treatment group of 500 µg / ml, and F- Pbl -3d is a fermented white spotted radish larvae extract treatment group by concentration. ** indicates that the expression of COLIA1 was significantly increased in TGF-β1 treatment compared to the negative control group, and p <0.01. # Indicates that the expression of COLIA1 in the F- Pbl- 0d parallel treatment group was significantly decreased compared to the TGF-β1 treatment group, and p <0.05. @@ means that the expression of COLIA1 in the TGF-β1 and F- Pbl-
Figure 4 is a result confirming the antioxidant effect of the white spotted radish larvae extract treatment. H 2 O 2 was treated to induce oxidation. Control is a negative control group without any treatment, F- Pbl -0d is a non-fermented white spotted radish larvae extract treatment group of 500 ㎍ / ㎖, F- Pbl -3d is a fermented white spotted larvae extract treated group by concentration to be. ** means that the intensity of dichlorofluorescein (DCF) significantly increased when H 2 O 2 treatment, compared to the negative control group, p <0.01. ## means that the intensity of DCF of the F- Pbl- 0d parallel treatment group was significantly decreased compared to the H 2 O 2 treatment group, and p <0.01. @@ means that it has H 2 O 2 and F- Pbl -3d DCF strength is significantly reduced in the 50㎍ / ㎖ treatment groups than in the H 2 O 2 and F- Pbl -0d treatment group, and, p <0.01 .
Figure 5 is the result confirming the activity of AST (A) and ALT (B) by white spotted flower larva extract treatment. H 2 O 2 was treated to induce the activity of the enzyme. Control is a negative control without any processing, and diphosphoinositide (DPI) is a positive control. FF- Pbl- 0d is a non-fermented white spotted radish larvae extract treatment group of 500 µg / ml, and F- Pbl -3d is a fermented white spotted radish larvae extract treatment group by concentration.
본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 기능 개선용 건강기능식품 조성물에 관한 것이다. The present invention relates to a health functional food composition for improving liver function containing fermented white spotted radish larvae extract as an active ingredient.
상기 발효 흰점박이꽃무지 유충은 흰점박이꽃무지 유충에 고초균(Bacillus subtilis)을 혼합하여 발효한 것이 바람직하지만, 이에 제한되는 것은 아니다. The fermented white spotted flower larva is preferably fermented by mixing Bacillus subtilis with the white spotted flower larva, but is not limited thereto.
상기 발효는 25~35℃에서 2~5일 동안 이루어지는 것이 바람직하고, 더욱 바람직하게는 30℃에서 3일 동안 발효하는 것이지만, 이에 한정하는 것은 아니다. The fermentation is preferably made for 2 to 5 days at 25 ~ 35 ℃, more preferably at 3 ℃ fermentation for 3 days, but is not limited thereto.
본 발명의 일 구현 예에서, 발효 흰점박이꽃무지 유충 추출물은 C1~C4의 저급 알코올, 물 또는 이들의 혼합물을 용매로 이용하여 추출한 것이 바람직하고, 더욱 바람직하게는 물을 이용하여 추출하는 것이지만, 이에 제한되지 않는다.In one embodiment of the present invention, fermented white spotted radish larvae extract is preferably extracted using a lower alcohol, water or a mixture thereof of C 1 ~ C 4 as a solvent, more preferably extracted using water But is not limited thereto.
본 발명의 일 구현 예에서 상기 발효 흰점박이꽃무지 유충의 추출은 발효 흰점박이꽃무지 건조분말 1 중량부에 대하여 5~20 중량부의 용매를 첨가하여 추출하는 것이 바람직하고, 더욱 바람직하게는 발효 흰점박이꽃무지 건조분말 1 중량부에 대하여 10 중량부의 용매를 첨가하여 추출하는 것이지만, 이에 제한되는 것은 아니다.In one embodiment of the present invention, the extraction of the fermented white spotted radish larvae is preferably extracted by adding 5 to 20 parts by weight of a solvent based on 1 part by weight of the fermented white spotted radish radish powder, more preferably fermented white Although it extracts by adding 10 weight part solvent with respect to 1 weight part of dry spotted flower powder, it is not limited to this.
본 발명의 일 구현 예에서, 상기 간 기능 개선용 조성물은 H2O2에 의해 증가된 AST 또는 ALT의 활성을 감소시키는 특징이 있다.In one embodiment of the present invention, the composition for improving liver function is characterized by reducing the activity of AST or ALT increased by H 2 O 2 .
본 발명의 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 발포정 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있지만, 이에 제한되지 않는다. The dietary supplement composition of the present invention may be prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup effervescent tablet and beverage, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강 조절을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다. When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). Generally, in the preparation of foods or beverages, it is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the nutraceutical composition of the present invention. However, in the case of long-term intake for the purpose of health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다. There is no particular limitation on the kind of the food. Examples of foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages and vitamin complexes, and the like, includes all of the health food in the conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다. 상기 건강기능식품 조성물 외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. In addition, the health functional food composition of the present invention may be prepared as food, in particular functional food. Functional foods of the present invention include ingredients that are commonly added in food production, and include, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when prepared with a drink, in addition to the active ingredient, natural carbohydrates or flavoring agents may be included as additional ingredients. The natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol, and the like. The flavoring agent may be a natural flavoring agent (eg, taumartin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.). Various nutritional supplements, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid Carbonation agent etc. which are used for a drink can be contained further.
또한, 본 발명은 발효 흰점박이꽃무지 유충 추출물을 유효성분으로 함유하는 간 섬유화 및 간경변의 예방 또는 치료용 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention or treatment of liver fibrosis and cirrhosis of the fermented white spotted radish larvae extract as an active ingredient.
본 발명의 간 섬유화 및 간경변의 예방 또는 치료용 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 포함할 수 있다.The pharmaceutical composition for preventing or treating liver fibrosis and cirrhosis of the present invention may include appropriate carriers, excipients and diluents commonly used in the preparation of the pharmaceutical composition.
본 발명에 따른 조성물의 약학적 투여 형태는 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. 본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제제, 외용제, 좌제 및 주사제의 형태로 제형화하여 사용될 수 있다. 본 발명의 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 유효성분에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로오스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이 외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 본 발명의 약학 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.
The pharmaceutical dosage forms of the compositions according to the invention can be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection. The pharmaceutical compositions according to the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and injections, respectively, according to conventional methods. . Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate And various compounds or mixtures including cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, or the like. Mix is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives are included. Can be. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. The preferred dosage of the pharmaceutical composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. These preparations and examples are only intended to explain the present invention more specifically, it is apparent to those skilled in the art that the scope of the present invention is not limited thereto.
제조예Production Example 1. 발효 굼벵이( 1. Fermented Slugs ( 흰점박이꽃무지White spotted flower solid 유충) 추출물 및 Larvae) extract and 비발효Non-fermentation 굼벵이 추출물의 제조 Preparation of Slugs Extract
(1) 발효 굼벵이 추출물의 제조(1) Preparation of fermented slug extract
굼벵이는 열풍 건조한 후 분말화 하였다. 굼벵이 분말은 121℃에서 15분 동안 멸균 후 시료로 사용하였다. Slugs were powdered after hot air drying. The slug powder was sterilized at 121 ° C. for 15 minutes and used as a sample.
발효에 사용한 균주는 고초균(Bacillus subtilis)이고, 동결하여 보관된 균주를 30℃, 100rpm 조건하에 1일 동안 OD 660nm 값이 1.7~1.8이 될 때까지 전 배양한 후, 균주의 활성을 상승시키기 위하여 30℃, 100rpm 조건하에 1일 동안 OD 660nm 값이 1.7~1.8이 될 때까지 1차 계대배양하였다. 그 후 3000rpm에서 10분 동안 원심분리하여 균체(pellet)만 획득한 후 멸균수를 1:1 중량비로 혼합하여 균체를 현탁하였다. 그 후 멸균한 굼벵이 시료 300g에 균주 300㎖를 접종한 후 촉촉해질 정도로 멸균수를 추가하였으며, 중간 중간 멸균수로 버무려주며 30℃에서 3일 동안 발효하였다. The strain used for fermentation was Bacillus subtilis ), and the frozen and stored strains were pre-incubated at 30 ° C. and 100 rpm for 1 day until the OD 660 nm value was 1.7-1.8, and then increased to 1 days under 30 ° C. and 100 rpm conditions. Primary passage was performed until the OD 660nm value is 1.7 ~ 1.8. Thereafter, only the cells were obtained by centrifugation at 3000 rpm for 10 minutes, and then, the sterile water was mixed in a 1: 1 weight ratio to suspend the cells. Then, after inoculating 300 ml of the sterilized slug sample, 300 ml of the strain was added to the sterile water enough to moisturize, fermented with intermediate intermediate sterilized water and fermented at 30 ° C. for 3 days.
발효 후 굼벵이 발효물은 50℃에서 5시간 동안 열풍 건조한 후 분말화하였으며, 분말 1 중량부에 대하여 10 중량부의 물을 첨가한 후 37℃에서 24시간 동안 열수 추출하였다. After fermentation, slugs fermented products were powdered after hot air drying at 50 ° C. for 5 hours, and 10 parts by weight of water was added to 1 part by weight of powder, followed by hot water extraction at 37 ° C. for 24 hours.
굼벵이 발효물의 열수 추출물은 감압여과 후 실험에 사용하였다.
The hydrothermal extract of slug fermentation was used for the experiment after filtration under reduced pressure.
(2) 비발효 굼벵이 추출물의 제조(2) Preparation of non-fermented slug extract
열풍건조한 후 멸균한 굼벵이 시료 1 중량부에 대하여 10 중량부의 물을 첨가한 후 37℃에서 24시간 동안 열수 추출하였다. After hot air drying, 10 parts by weight of water was added to 1 part by weight of sterilized slugs, followed by hot water extraction at 37 ° C. for 24 hours.
굼벵이 열수 추출물(비발효 굼벵이 추출물)은 감압여과 후 실험에 사용하였다.
Slugs hot water extract (non-fermented slug extract) was used for the experiment after filtration under reduced pressure.
실시예Example 1. 발효 굼벵이 추출물의 세포 생존율 확인 1. Confirmation of cell viability of fermented slug extract
시료의 안정성을 알아보기 위해 3-(4,5-디메틸티아졸-2-일)-5-(3-카르복시메톡시페닐)-2-(4-설포페닐)-2H-테트라졸리움(MTS, promega, USA) 분석 방법을 통해 정상 세포주인 인간 신장 상피 세포인 293T 세포의 생존율을 측정하였다. To determine the stability of the sample, 3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS, promega, USA) was used to determine the viability of 293T cells, human kidney epithelial cells.
세포를 96 웰 플레이트에 4x103 세포/웰 씩 분주한 다음 농도별(50, 250, 500㎍/㎖)로 시료를 처리하여 37℃, 5% CO2 조건으로 48시간 동안 배양하였다. 배양 후 2mg/㎖의 농도로 PBS에 희석된 MTS 용액 20㎕를 첨가하고 4시간 동안 재배양한 후 마이크로플레이트 리더로 490nm에서 흡광도를 측정하였다. 세포의 생존능력은 다음의 식에 따라 계산하였다.Cells were dispensed at 4 × 10 3 cells / well in 96 well plates and then sampled at different concentrations (50, 250, 500 μg / ml) and incubated for 48 hours at 37 ° C. and 5% CO 2 . After incubation, 20 μl of a solution of MTS diluted in PBS at a concentration of 2 mg / ml was added and cultured for 4 hours. Cell viability was calculated according to the following equation.
[식 1][Equation 1]
세포 생존율(%)=시료 첨가군의 흡광도/대조군의 흡광도×100Cell survival rate (%) = absorbance of the sample addition group / absorbance of the control group x 100
그 결과, 도 1에 개시된 바와 같이 발효 굼벵이 추출물 및 비발효 굼벵이 추출물은 모두 세포독성이 없는 것을 확인하였다.
As a result, as shown in Figure 1, both the fermented slug extract and the non-fermented slug extract were confirmed to have no cytotoxicity.
실시예Example 2. 발효 굼벵이 추출물의 간 섬유화 및 간경변의 개선 기능성 분석 2. Functional analysis of liver fibrosis and cirrhosis of fermented slug extract
(1) TGF-β1 처리에 의해 증가된 세포 증식 억제효과(1) Increased cell proliferation inhibitory effect by TGF-β1 treatment
간 섬유화와 밀접한 관련이 있는 인간 간 성상세포(human hepatic stellate cell line, LX-2)의 증식 억제효과를 확인하기 위해 TGF-β1 처리에 의해 세포 증식을 촉진시킨 후 발효 굼벵이 추출물을 처리하여 억제하는 효과를 확인하였다. In order to confirm the proliferation inhibitory effect of human hepatic stellate cell line (LX-2), which is closely related to liver fibrosis, TGF-β1 treatment was used to promote cell proliferation and to inhibit fermented slug extract. The effect was confirmed.
인간 간 성상세포(LX-2 cells, obtained from Dr. Fridemann, Columbia University, New York, USA)의 배양은 37℃ 대기와 5% CO2 조건에서 시행하였다. 간 성상세포는 100mm 배양접시(Falcon, Becton Dickinson, Fanklin Lakes, NJ, USA)에서 배양하였으며, 10%(v/v) 열 비활성의 FBS(fetal bovine serum, Invitrogen, USA)와 항생제(Invitrogen)가 포함된 DMEM(Dulbecco's modified Eagle's, Invitrogen)을 사용하였다.Cultures of human liver stellate cells (LX-2 cells, obtained from Dr. Fridemann, Columbia University, New York, USA) were performed at 37 ° C and 5% CO 2 . Hepatic stellate cells were cultured in a 100 mm dish (Falcon, Becton Dickinson, Fanklin Lakes, NJ, USA), and 10% (v / v) heat inactive FBS (fetal bovine serum, Invitrogen, USA) and antibiotic (Invitrogen) Included DMEM (Dulbecco's modified Eagle's, Invitrogen) was used.
세포를 96 웰 플레이트에 4x103 세포/웰 씩 분주한 다음 10ng/㎖의 TGF-β1 및 농도별(50, 250, 500㎍/㎖) 발효 굼벵이 추출물 및 500㎍/㎖의 비발효 굼벵이 추출물을 처리하여 37℃, 5% CO2 조건으로 48시간 동안 배양하였다. 배양 후 2mg/㎖의 농도로 PBS에 희석된 MTS 용액 20㎕를 첨가하고 4시간 동안 재배양한 후 마이크로플레이트 리더로 490nm에서 흡광도를 측정하였다. 세포 증식률은 상기 식 1의 세포 생존율 계산법에 따라 계산하였다.Cells were dispensed at 4 × 10 3 cells / well in 96 well plates and treated with 10 ng / ml TGF-β1 and concentration-specific (50, 250, 500 μg / ml) fermented slug extract and 500 μg / ml non-fermented slug extract Incubated for 48 hours at 37 ℃, 5% CO 2 conditions. After incubation, 20 μl of a solution of MTS diluted in PBS at a concentration of 2 mg / ml was added and cultured for 4 hours. Cell proliferation was calculated according to the cell viability calculation method of Formula 1.
그 결과, 도 2에 개시된 바와 같이 TGF-β1 처리에 의해 증가된 세포 증식효과가 굼벵이 추출물 처리시 감소하였으며, 이러한 감소효과는 발효 굼벵이 추출물 처리에 의해 더욱 현저하다는 것을 확인하였다.
As a result, as shown in FIG. 2, the cell proliferation effect increased by TGF-β1 treatment was reduced in the treatment of slug extract, and it was confirmed that this reduction effect was more remarkable by the treatment of fermentation slug extract.
(2) COLⅠA1(collagen type Ⅰα 1 chain) 유전자 발현 확인(2) Confirmation of COLIA1 (collagen type Iα 1 chain) gene expression
LX-2 세포를 6-웰 플레이트에 분주하고(2.5×105/웰) 24시간 후 농도별 발효 굼벵이 추출물 및 을 농도별로 처리하고, 3시간 뒤 TGF-β1(10ng/㎖)을 추가한 뒤 24시간 동안 배양하였다. LX-2 cells were aliquoted into 6-well plates (2.5 × 10 5 / well), and after 24 hours, the fermentation slug extracts and concentrations were treated by concentration, and after 3 hours, TGF-β1 (10 ng / ml) was added. Incubated for 24 hours.
RNA의 분리는 TRIZOL 용액(MRC, Cincinnati, OH, USA)을 사용하여 제조사의 방법에 따라 총 RNA를 분리하였으며, 분리된 총 RNA는 나노분광광도계(Applied Biosystems, Foster City, CA)를 사용하여 정량하였다. 분리된 총 RNA(1㎍)는 cDNA 합성을 위해 ImProm-IITM 역전사 시스템(Promega, Madison, WI, USA)을 사용하였고, 합성된 cDNA는 나노분광광도계(Applied Biosystems, Foster City, CA)를 사용하여 정량하였다. 합성된 cDNA(200ng) 내 COLⅠA1의 유전자 발현량은 SYBR 그린 마스터 믹스 키트(QuantiMix SYBR Kit, Biosystems)를 사용하여 RG-6000 Real-Time PCR 시스템(Corbett Life Sciences, Sydney, NSW, Australia)을 통해 확인하였다. RNA was isolated using TRIZOL solution (MRC, Cincinnati, OH, USA) according to the manufacturer's method, total RNA was isolated and the total RNA was quantified using a nano-spectrophotometer (Applied Biosystems, Foster City, CA) It was. Total RNA isolated (1 μg) was used for the ImD Prom-II ™ reverse transcription system (Promega, Madison, Wis., USA) for cDNA synthesis, and the synthesized cDNA was used with nano-spectrophotometers (Applied Biosystems, Foster City, CA). Quantification by Gene expression level of COLIA1 in synthesized cDNA (200ng) was confirmed by RG-6000 Real-Time PCR system (Corbett Life Sciences, Sydney, NSW, Australia) using SYBR Green Master Mix Kit (QuantiMix SYBR Kit, Biosystems). It was.
그 결과, 도 3에 개시된 바와 같이 TGF-β1 처리에 의해 증가된 COLⅠA1 유전자 발현은 굼벵이 추출물 처리에 의해 감소하였으며, 특히 발효 굼벵이 추출물을 처리하였을 경우 모든 농도에서 COLⅠA1의 유전자 발현량이 현저히 감소하는 것을 확인하였다.
As a result, as shown in FIG. 3, the COLIA1 gene expression increased by TGF-β1 treatment was decreased by the slug extract treatment, and in particular, when the fermented slug extract was treated, the gene expression level of COLIA1 was significantly decreased at all concentrations. It was.
실시예Example 3. 발효 굼벵이 추출물의 항산화력 분석 3. Antioxidant Activity of Fermented Slug Extract
발효 굼벵이 추출물의 ROS(Reactive Oxygen Species) 소거능을 확인하기 위해 간암 세포인 HepG2를 이용하였다. 간세포 내 ROS의 양은 형광 프로브인 DCF-DA을 사용하여 측정하였다. HepG2, a liver cancer cell, was used to confirm the ROS (Reactive Oxygen Species) scavenging ability of fermented slug extract. The amount of ROS in hepatocytes was measured using DCF-DA, a fluorescent probe.
간암 세포인 HepG2는 한국세포주은행(Korean cell line bank, KCLB)에서 분양받았으며, MEM 배지에 10%(v/v) FBS(feral bovine serum)와 1%(v/v) 100 units/㎖의 페니실린-스트레프로마이신(penicillin-strepromycin)이 함유된 배지를 사용하여, 37℃, 5% CO2 배양기에서 배양하였다.HepG2, a liver cancer cell, was distributed by the Korean Cell Line Bank (KCLB), and 10% (v / v) FBS (feral bovine serum) and 1% (v / v) penicillin in MEM medium. Culture was carried out in a 37 ° C., 5% CO 2 incubator using a medium containing penicillin-strepromycin.
HepG2 세포들을 96 웰 플레이트에 1x104 세포/웰 씩 분주하고 37℃, 5% CO2 조건으로 24시간 동안 배양하였다. 배양 후 배양액에 농도별(50, 250, 500㎍/㎖) 발효 굼벵이 추출물, 3μM의 DCF-DA(2',7'-Dichlorofluorescin diacetate) 및 50μM의 H2O2를 1시간 동안 처리한 다음 형성된 세포 내 과산화물을 여기(excitation) 파장 485nm, 방출(emission) 파장 535nm을 이용하여 형광을 측정하였다.HepG2 cells were dispensed in 96 well plates at 1 × 10 4 cells / well and incubated at 37 ° C., 5% CO 2 for 24 hours. After incubation, the culture solution was treated with concentration-specific (50, 250, 500 µg / ml) fermented slug extract, 3 μM of DCF-DA (2 ', 7'-Dichlorofluorescin diacetate), and 50 μM of H 2 O 2 for 1 hour. Intracellular peroxides were measured for fluorescence using an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
[식 2][Equation 2]
ROS 소거능=시료 첨가군의 흡광도/대조군의 흡광도×100ROS scavenging ability = absorbance of the sample addition group / absorbance of the control group x 100
그 결과, 도 4에 개시된 바와 같이 H2O2에 의해 증가된 세포 내 ROS가 굼벵이 추출물 처리시 감소하였고, 특히 발효 굼벵이 추출물을 처리한 군에서 비발효 굼벵이 추출물을 처리한 군에 비해 ROS 감소량이 현저하였다.
As a result, as shown in FIG. 4, the intracellular ROS increased by H 2 O 2 decreased during the treatment of slug extract, especially in the group treated with fermented slug extract, the amount of ROS reduction compared to the group treated with the non-fermented slug extract. Remarkable
실시예Example 4. 발효 굼벵이 추출물의 간 기능 개선 분석 4. Analysis of liver function improvement of fermented slug extract
간세포 내 발효 굼벵이 추출물 처리시 AST(aspartate aminotransferase) 및 ALT(alanine aminotransferase) 수치를 측정하기 위하여 아산제약의 GOT(AST), GPT(ALT) 측정용 시액 키트를 사용하여 측정하였다. HepG2 세포들을 96 웰 플레이트에 1x104 세포/웰 씩 분주하고, 37℃, 5% CO2 조건으로 24시간 동안 배양하였다.In order to measure the AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels in the treatment of fermented slug extract in hepatocytes, it was measured using a reagent kit for measuring GOT (AST) and GPT (ALT) of Asan Pharmaceutical. HepG2 cells were dispensed in 96 well plates at 1 × 10 4 cells / well and incubated for 24 hours at 37 ° C., 5% CO 2 .
그 후 굼벵이 추출물을 농도별로 2시간 전처리한 후, 간독성 물질로 사용된 H2O2 처리한 다음 배양기에서 37℃, 5% CO2 조건으로 24시간 동안 배양한 후 상등액을 취하여 AST와 ALT를 각각 측정하였다.Then, the slug extract was pretreated for 2 hours by concentration, treated with H 2 O 2 used as a hepatotoxic substance, and then incubated for 24 hours at 37 ° C. and 5% CO 2 in an incubator, followed by taking a supernatant to extract AST and ALT, respectively. Measured.
AST 및 ALT는 하기 식 3의 방법으로 계산하였다.AST and ALT were calculated by the method of the following equation.
[식 3][Equation 3]
AST(또는 ALT) 활성(IU/ℓ)=B/(T2-T1)×VAST (or ALT) activity (IU / L) = B / (T2-T1) × V
B: 피루빈산염 표준곡선에서 피루빈산염의 양(pyruvate amount from pyruvate standard curve)B: pyruvate amount from pyruvate standard curve
T1: 첫 번째 읽은 시간(time of the first reading)T1: time of the first reading
T2: 두 번째 읽은 시간(time of the second reading)T2: time of the second reading
V: 반응 웰에 추가된 초기 샘플 량(original sample volume added into the reaction well)V: original sample volume added into the reaction well
그 결과, 도 5에 개시된 바와 같이 H2O2에 의해 증가된 AST 및 ALT가 굼벵이 추출물 처리시 감소하는 것을 확인하였으며, 발효 굼벵이 추출물이 비발효 굼벵이 추출물에 비해 AST 및 ALT를 감소하는 효과가 현저하였다. As a result, it was confirmed that the AST and ALT increased by H 2 O 2 decreased as the slug extract was treated as shown in FIG. 5, and the effect of reducing the AST and ALT in the fermented slug extract was significantly lower than that of the non-fermented slug extract. It was.
이를 통해 굼벵이 추출물, 특히 발효 굼벵이 추출물은 간 기능 개선효과가 있다는 것을 확인하였다. Through this, it was confirmed that slug extract, particularly fermented slug extract, had an effect on improving liver function.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180098974A KR102098079B1 (en) | 2018-08-24 | 2018-08-24 | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180098974A KR102098079B1 (en) | 2018-08-24 | 2018-08-24 | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200023576A true KR20200023576A (en) | 2020-03-05 |
| KR102098079B1 KR102098079B1 (en) | 2020-04-08 |
Family
ID=69803888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180098974A KR102098079B1 (en) | 2018-08-24 | 2018-08-24 | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102098079B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220000132A (en) | 2020-06-25 | 2022-01-03 | 주식회사 휴비스트제약 | Composition comprising Protaetia brevitarsis seulensis larva extracts for improving sleep |
| KR20240008069A (en) | 2022-07-11 | 2024-01-18 | 농업회사법인 딥루티드팜 주식회사 | Composition for improving thrombosis and improving liver function by containing a slug extract fermented with Bacillus subtilis derived from slug feces as an active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130066474A (en) * | 2011-12-12 | 2013-06-20 | 박근호 | Health functional food composition effective for liver function and blood circulation and method for its production |
| KR101852840B1 (en) * | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
-
2018
- 2018-08-24 KR KR1020180098974A patent/KR102098079B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130066474A (en) * | 2011-12-12 | 2013-06-20 | 박근호 | Health functional food composition effective for liver function and blood circulation and method for its production |
| KR101852840B1 (en) * | 2018-01-02 | 2018-04-27 | 주식회사 한미양행 | Hepatoprotective composition comprising enzyme treated larva |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Life Science, 2018. 7. 28, Vol.28, No.7, pp.827-834 1부.* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220000132A (en) | 2020-06-25 | 2022-01-03 | 주식회사 휴비스트제약 | Composition comprising Protaetia brevitarsis seulensis larva extracts for improving sleep |
| KR20240008069A (en) | 2022-07-11 | 2024-01-18 | 농업회사법인 딥루티드팜 주식회사 | Composition for improving thrombosis and improving liver function by containing a slug extract fermented with Bacillus subtilis derived from slug feces as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102098079B1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100988072B1 (en) | Fermented dendropanax morbifera lev. products and a pharmaceutical composition comprising the same | |
| KR20170020443A (en) | Cyclic dipeptide-containing composition | |
| KR102048309B1 (en) | Composition for preventing, improving or treating thrombosis comprising extract of fermented Tenebrio molitor as effective component | |
| JP2006083151A (en) | Composition for preventing and ameliorating osteoporosis | |
| KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
| KR20090025469A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases or the alleviation of pain containing extract of gastrodia elata | |
| KR20180040534A (en) | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
| KR102098079B1 (en) | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component | |
| CN109069562A (en) | Polysaccharide digests inhibitor | |
| KR102350102B1 (en) | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component | |
| KR20170106187A (en) | Antioxidant Composition | |
| KR20200070081A (en) | Lactobacillus salivarius having anticariogenic activities and composition comprising the same | |
| KR20200089040A (en) | Composition for preventing, improving or treating cancer comprising Abeliophyllum distichum extract as effective component | |
| KR101302652B1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS COMPRISING α-GLUCOSIDASE INHIBITOR AND BREWER'S DRIED YEAST | |
| KR101358197B1 (en) | Composition for promoting leptin secretion comprising specific compounds as effective component | |
| KR101446784B1 (en) | Pharmaceutical composition for anticancer comprising extract of sea cucumber or its fraction as effective component | |
| JP6418456B2 (en) | Uric acid excretion promoting composition | |
| JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
| KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
| KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
| KR101490794B1 (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia | |
| KR20170077980A (en) | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
| KR100842054B1 (en) | Composition containing extracts of Glycyrrhizin Radix Praepara or compounds isolated therefrom for the Blood Glucose-Lowering effect | |
| KR101622032B1 (en) | Pharmaceutical composition comprising Cymbidium extract for preventing or treating muscle atrophy | |
| JP2006265142A (en) | Body fat accumulation inhibiting or decreasing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |